Health Policy and Management (보건행정학회지)

Korean Academy of Health Policy and Management (한국보건행정학회)
권호 표지
DOI QR코드

DOI QR Code

Measuring Utility for Menopausal Symptoms Based on Time Trade-Off and Visual Analogue Scale Methods

시간교환법과 시각화척도 방법을 이용한 폐경 후 에스트로겐 결핍증에 대한 효용 측정

  • Lim, Seung-Ji (Department of Public Health, Yonsei University Graduate School) ;
  • Kang, Hye-Young (Graduate School of Public Health, Institute of Health Services Research, Yonsei University) ;
  • Kang, Young-Ju (Institute of Health Services Research, Yonsei University) ;
  • Lee, Byung-Seok (Department of Obstetrics and Gynecology, College of Medicine, Yonsei University) ;
  • Park, Hyoung-Moo (Department of Obstetrics and Gynecology, College of Medicine, Chung-ang University) ;
  • Shin, Dong-Hyeok (Mizmedi Hospital)
  • 임승지 (연세대학교 대학원 보건학과) ;
  • 강혜영 (연세대학교 보건대학원, 연세대학교 보건정책 및 관리연구소) ;
  • 강영주 (연세대학교 보건정책 및 관리연구소) ;
  • 이병석 (연세대학교 의과대학 산부인과) ;
  • 박형무 (중앙대학교 의과대학 산부인과) ;
  • 신동혁 (미즈메디병원 가정의학과)
  • Published : 2007.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was conducted to measure health-related utility for post-menopausal symptoms among Korean woman. A survey questionnaire was developed to measure utility based on visual analogue scale(VAS) and time trade-off method (TTO). From January 29 to February 3, 2007, a face-to-face interview was conducted with 274 women aged 45 to 60 to ask about their subjective utility for hypothetical health status of mild or severe post-menopausal symptoms. Among the participants, 160 were recruited from outpatient departments of 3 hospitals and 114 from 2 sports centers located in Seoul. For mild symptom, the average utility score of the respondents was $0.63{\pm}0.14$ based on VAS and $0.61{\pm}0.26$ based on ITO. For severe symptoms, the average utility was $0.39{\pm}0.16$(VAS) and $0.44{\pm}0.27$ (TTO). For severe symptom, a higher utility score was observed for TTO than for VAS, which is consistent with earlier studies and thus supports the validity of the utility measurement in this study. Overall, the severity of post-menopausal symptoms of the respondents themselves was not significantly associated with the utility score that the respondents answered for hypothetical health status. Multiple regression analysis results showed that the utility score was significantly higher among respondents with older age, higher education, higher family income, and from hospitals. It is expected that the utility score measured in this study will enhance the understanding of the quality of life of women after menopause and will be used to conduct cost-utility analysis of health care interventions to treat post-menopausal symptoms.

Keywords

References

  1. 김주영,조장철,힘승현,정소망,류철희 김종덕. 폐경기 여성에서 호르몬 대체요법에 따른 삶의 질에 대한 평가. 대한산부인과학회지 1998;41(9):2429-2435
  2. 김진수,김상엽,이해혁,이명환,문원실,이석민 등. 폐경기 전후 여성의 임상적 특정에 관한 연구. 대한산부인과학회지 1998;41(8):2201-2206
  3. 대한산부인과학회 교과서 편찬위원회. 부인과학, 제3판. 서울:도서출판 칼빈서적;1997
  4. 박형무, 서유석, 허민. 한국 폐경 여성 인구의 동태 및 추이. 대한폐경학회지 1998;4(1):61-71
  5. 오영림, 윤건배, 김형중, 이천준, 김흥열. 갱년기여성에서 호르몬 보충요법과 Alendronate가 골대사 및 골밀도에 미치는 영향에 관한 연구. 대한폐경학회지 2004;10(2):111-120
  6. 유영옥. 갱년기 호르몬치료의 부작용과 그 대처방법. 대한폐경학회지 2004;10(1):14-20
  7. 이영진, 홍민, 한혁동. 강원도 지역 여성의 폐경기, 갱년기 증상에 대한 임상적 고찰.c 1995;1(1):35-41
  8. 이종화, 정연강, 박형무, 박재순, 염순교. 중년 여성이 호소하는 갱년기 증상에 관한 연구. 대한폐경학회지 2000;6(2):141-155
  9. 이후연, 김희남, 김한중, 최재영, 박은철. 인공와우 이식의 비용-효용 분석. 예방의학회지 2004;37(4):353-358
  10. 한인권, 박경옥, 김효민, 조남한. 중년여성의 갱년기 증상과 그 인지도에 관한 연구. 대한폐경학회지 1998;4(1):3-15
  11. 홍억기, 김재수, 조한성, 한인권, PMS(Post-/Premenopausal Sundrome)여성에 대한 대체요법의 유효성 및 안정성. 한국생물공학회지 2004;10(2):121-127
  12. Barrett-Connor E. Hormone replacement therapy. BMJ 1998;317(7156):457-461 https://doi.org/10.1136/bmj.317.7156.457
  13. Beija I, Salem KB, Touzi M, Bergaoui N. Measuring utility by the time trade-off method in tunisian rheumatoid arthritis patients. Clin Rheumatol 2005;25(1):38-41
  14. Bramlett RE, Bothe AK, Franic DM. Using preference-based measures to assess quality of life in stuttering. J Speech Lang Hear Res 2000;49(2):381-94 https://doi.org/10.1044/1092-4388(2006/030)
  15. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analysis. Value Health 2000;9(4):213-218 https://doi.org/10.1111/j.1524-4733.2006.00116.x
  16. Brazier JE, Roberts J, Platts M, Zoellner YF. Estimating a preference-based index for a menopause specific health quality of life questionnaire. Health Qual Life Outcomes 2005;3:13-21 https://doi.org/10.1186/1477-7525-3-13
  17. Brown WJ, Mishra GD, Dobson A. Changes in physical symptoms during the menopause transition. Int J Behav Med, 2002;9(1):53-67 https://doi.org/10.1207/S15327558IJBM0901_04
  18. Bush TL, Miller TV. Effect of pharmarcologic agent used during menopause. Menopause physiology ad pharmacology Chicago, Year Book Medical Publisher 1987:185-205
  19. Cheng AK, Rubin HR, Powe NR, Mellon NK, Francis HW, Niparko JK Cost-utility analysis of the cochlear implant in children. JAMA 2000;284(7):850-856 https://doi.org/10.1001/jama.284.7.850
  20. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307(2):836-840 https://doi.org/10.1136/bmj.307.6908.836
  21. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet and Gymecol 2000;96(3):351-358 https://doi.org/10.1016/S0029-7844(00)00930-3
  22. Dunmmond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Ch 6. Cost-Utility Analysis. In: Methods for the economic evaluation of health care programmes. 3rd edition. New York:Oxford University Press:2005a. p.205
  23. Dunmmond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Ch 6. Cost-Utility Analysis. In: Methods for the economic evaluation of health care programmes. 3rd edition. New York:Oxford University Press:2005b. p.151-153
  24. Gambrell R Jr, Bagnell CA, Greenblatt RB. Role of estrogen and progesterone in the etiology and prevention of endometrial cancer: review. American journal of Obstet and Gynecol 1983; 62(6): 696-707
  25. Hardy R, Kuh D. Change in psychological and vasomotor symptom reportingduring the menopause. Obstetrics and Gynecology 2000;96(3):351-358 https://doi.org/10.1016/S0029-7844(00)00930-3
  26. Hvas L, Thorwen H, Sondergaard K. Discussing menopause in general practice. Maturitas 2003;46(2):139-146 https://doi.org/10.1016/S0378-5122(03)00164-6
  27. Jokinen K, Pautava P, Makinen J, Ojanlatva A, Sundell J, Helenius H. Experience of climateric symptoms among 42-46 and 52-56-year-old women. .Maturitas 2003;46(3):199-205 https://doi.org/10.1016/S0378-5122(03)00216-0
  28. Miller MD, Ferris DG. Measurement of subjective phenomena in primary care research: the visual analogue scale. Fam pract Res J 1993;13(1):15-24
  29. Mishra G, Kuh D. Perceived change in quality of life during the menopause. Soc Sci Med 2006;62(1):93-102 https://doi.org/10.1016/j.socscimed.2005.05.015
  30. Philip BK. Parametric statistics for evaluation of the visual analog scale. Anesth Analg 1990;7(6):710
  31. Sakett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chron Dis 1978;31(11):697-704 https://doi.org/10.1016/0021-9681(78)90072-3
  32. Saw SM, Gazzard G, Gomezeralta C, Eong KGA, Seah S. Utility assessment among cataract surgery patients. J Cataract Refract Surg 2005;31(4):785-791 https://doi.org/10.1016/j.jcrs.2004.08.043
  33. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility Assessment among Patients with dry eye disease. Ophthalmology 2004;110(7):1412-1419 https://doi.org/10.1016/S0161-6420(03)00462-7
  34. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5(1):1-30 https://doi.org/10.1016/0167-6296(86)90020-2
  35. Whittington R, Faulds D. hormone replacement therapy. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency. Pharmacoeconomics 1994;5(5):419-445 https://doi.org/10.2165/00019053-199405050-00008
  36. Zapantis G, Santoro N. The menopausal transition: Characteristics and management. Best Practice and Research Clinical Endocrinology Metabolism 2003;17:33-52 https://doi.org/10.1016/S1521-690X(02)00081-7

Cited by

  1. Economic evaluation of a weekly administration of a sustained-release injection of recombinant human growth hormone for the treatment of children with growth hormone deficiency vol.52, pp.11, 2009, https://doi.org/10.3345/kjp.2009.52.11.1249